Megestrol

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Megestrol

Clinical data
Pregnancy category	contraindicated
ATC code	G03AC05 (WHO) G03DB02 (WHO), L02AB01 (WHO)
Pharmacokinetic data
Elimination half-life	34 hours
Identifiers
IUPAC name 17-acetyl-17-hydroxy-6,10, 13-trimethyl-2,8,9,11,12,14,15,16- octahydro-1H-cyclopenta[ a] phenanthren-3-one
CAS Number	3562-63-8
PubChem CID	19090
DrugBank	APRD01092
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C22H30O3
Molar mass	342.472 g/mol

For patient information, click here.

Megestrol is a progesterone derivative with antineoplastic properties used in the treatment of advanced carcinoma of the breast and endometrium. When given in relatively high doses, Megestrol can substantially increase appetite in most individuals, even those with advanced cancer.

Megestrol Acetate Oral Suspension (a form of Megestrol) is used primarily as an appetite enhancer. The method of appetite enhancement is not known, but it CAN cause hyperglycemia also known as high blood sugar[ http://www.megacees.com/megacees-side-effects.html].
Currently, it is manufactured under the trade name Megace [2]

Template:Sex hormones

Template:WikiDoc Sources